JAMA Network
About The Study: In this study, over a median of 8.6 years, low-dose aspirin was not associated with incident cancer among older adults, but cancer mortality risk was significantly elevated. However, the elevated cancer mortality risk seen with aspirin for participants in the randomized clinical trial (RCT) period did not persist into the post-RCT observation period, suggesting no legacy effect.
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
